Gary Clark: Unfiltered

Fidelity's estimated ETF capital gains are out. Beyond the tax headache, these numbers reveal key insights into market performance and fund strategy.

A C$30M financing, led by Pan American Silver, accelerates Galleon Gold's West Cache project and signals a strategic shift in the Timmins gold camp.

Despite volatile markets, Canada Nickel's oversubscribed C$15M offering signals strong investor faith in its massive, net-zero Crawford nickel project.

Beyond the headlines, Newmark's acquisition of Catella is a calculated bet on Paris and a masterclass in buying influence ahead of a market recovery.

Sustainable Green Team is patenting a system to turn tree trimmings into energy, soil, and crypto. Is this the future of the circular economy?

Kohl's makes its interim CEO permanent. We dive into why Michael Bender’s operational prowess and recent wins signal a strategic pivot for the retailer.

Capstone Green Energy secures a crucial $15M financing to repay debt, with insiders betting big on a strategic expansion into the AI data center market.

A micro-cap virtual dining firm partners with a tech giant. We unpack the savvy strategy behind GreetEat's move to scale up, de-risk, and win investor trust.

Janux Therapeutics is set to unveil key data for its cancer drug JANX007. The results could validate its precision platform and shake up the market.

Canacol Energy's cross-border bankruptcy is more than a corporate failure; it's a critical stress test for international law and Colombia's fragile energy supply.

Aquestive Therapeutics signals commercial readiness for its needle-free allergy film, setting up a high-stakes showdown in the multi-billion dollar market.

Enterprise Products Partners promotes internal candidate Michael ‘Tug’ Hanley to CCO, signaling stability and experience as the midstream giant navigates evolving energy markets and significant infrastructure investments.

A preliminary valuation of Oncotelic Therapeutics’ joint venture pipeline has reached $1.7 billion, spotlighting the potential of targeted nanomedicine and the growing appetite for innovative biotech assets in Hong Kong.

ENDRA Life Sciences’ thermoacoustic imaging technology aims to disrupt the liver disease diagnostics market with a cost-effective, accessible alternative to MRI. But can this financially challenged medtech firm deliver on its promise?

Controlled environment agriculture company expands retail footprint in Northeast, riding consumer demand for fresh, locally-sourced food while navigating a challenging financial landscape.

Plus Therapeutics secures national coverage with Humana, broadening access to CNSide®, a cutting-edge test for diagnosing and monitoring brain metastasis. This coverage, following UnitedHealthcare’s approval, signals a shift towards advanced diagnostics in cancer care.

Radiopharmaceutical developer Perspective Therapeutics is hitting the investor circuit, showcasing its alpha-emitting cancer therapies. With a crowded field and recent M&A activity, the company is seeking funding to advance its pipeline and scale manufacturing.

A joint venture between energy giants Enterprise and ExxonMobil expands NGL pipeline capacity out of the Permian Basin, signaling confidence in long-term growth and intensifying competition in the midstream sector.

SciSparc Ltd. and Clearmind Medicine Inc. are advancing a novel approach to treating depression with a non-hallucinogenic therapy. A recently filed patent application signals a commitment to innovative CNS treatments.

BeOne Medicines is poised to reshape hematological oncology with a diverse pipeline, highlighted by novel BTK degrader BGB-16673 and promising BCL2 inhibitor sonrotoclax. ASH 2025 presentations could be a key catalyst.